PYN Phynova

 

TIDMPYN 
 
RNS Number : 6861O 
Phynova Group PLC 
11 March 2009 
 

11 March 2009 
 
 
Phynova Group plc 
("Phynova" or the "Company") 
 
 
Availability of Report & Accounts 
 
 
The Company announces that the report and accounts for the year ended 30 
September 2008 has now been posted to shareholders and is available from the 
Company's website www.phynova.com. 
 
 
For further information, please contact: 
 
 
+------------------------------------------------------+-------------------------+ 
| Phynova Group plc                                    |       Tel: 01993 880700 | 
| John Pool (Executive Chairman)                       |                         | 
| Tony Mills (CEO Phynova Limited)                     |                         | 
| Robert Miller (CEO Phynova China Limited)            |                         | 
|                                                      |                         | 
+------------------------------------------------------+-------------------------+ 
| John East & Partners Limited                         |      Tel: 020 7618 2200 | 
| Simon Clements                                       |                         | 
|                                                      |                         | 
+------------------------------------------------------+-------------------------+ 
| Capital MS&L                                         |     Tel: 020 7 307 5330 | 
| Mary Clark/Anna Mitchell                             |                         | 
|                                                      |                         | 
+------------------------------------------------------+-------------------------+ 
 
 
Notes to editors: 
 
 
About Phynova 
 
 
Phynova (AIM: PYN) is a UK company developing new prescription pharmaceuticals 
derived from plants used in Chinese medicines. The Company is focused on viral 
and bacterial diseases, metabolic diseases and cancer. Phynova's lead product 
for hepatitis C has now completed a Phase I/II trial in the US. Two further 
products, for fatty liver disease and post-operative ileus, are targeted for 
entry to the clinic and there are a further four products in preclinical 
development. 
 
 
For further information please visit www.phynova.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 ACSSFMFFFSUSEID 
 

Phynova (LSE:PYN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Phynova (LSE:PYN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025